Growth Metrics

Gilead Sciences (GILD) EBIT Margin (2009 - 2026)

Gilead Sciences posted quarterly EBIT Margin of 37.16% for Q1 2026, up 360.0% year-on-year from 8.08% in Q1 2025, and up 48.41% on a QoQ basis from 25.03% in Q4 2025.

Gilead Sciences (GILD) has 18 years of EBIT Margin data on file, last reported at 37.16% in Q1 2026.

  • For the quarter ending Q1 2026, EBIT Margin rose 360.0% year-over-year to 37.16%; the trailing twelve-month figure through Mar 2026 stood at 34.88% (up 627.0% YoY), and the FY2025 full-year result was 34.04%, up 2826.0% from the prior year.
  • EBIT Margin for Q1 2026 stood at 37.16%, up from 25.03% in the prior quarter.
  • Across five years, EBIT Margin topped out at 42.82% in Q3 2025 and bottomed at 64.64% in Q1 2024.
  • The 5-year median for EBIT Margin is 32.4% (2024), against an average of 24.08%.
  • The widest annual swing landed in 2024, when EBIT Margin tumbled 9148 bps; it then soared 9820 bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 30.68% in 2022, then slipped by 26 bps to 22.66% in 2023, then soared by 43 bps to 32.4% in 2024, then declined by 23 bps to 25.03% in 2025, then surged by 48 bps to 37.16% in 2026.
  • The last three EBIT Margin figures came in at 37.16% (Q1 2026), 25.03% (Q4 2025), and 42.82% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 47.98%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 26.44%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 26.60%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -47.46%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 30.94%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 37.16%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -286.83%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -1.58%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 37.16%
Dec 31, 2025 25.03%
Sep 30, 2025 42.82%
Jun 30, 2025 34.93%
Mar 31, 2025 33.55%
Dec 31, 2024 32.40%
Sep 30, 2024 11.77%
Jun 30, 2024 38.02%
Mar 31, 2024 -64.64%
Dec 31, 2023 22.66%
Sep 30, 2023 37.20%
Jun 30, 2023 25.23%
Mar 31, 2023 26.84%
Dec 31, 2022 30.68%
Sep 30, 2022 40.29%
Jun 30, 2022 32.41%
Mar 31, 2022 2.99%
Dec 31, 2021 12.98%
Sep 30, 2021 51.77%
Jun 30, 2021 36.13%
Mar 31, 2021 44.99%
Dec 31, 2020 35.72%
Sep 30, 2020 30.42%
Jun 30, 2020 -58.00%
Mar 31, 2020 43.29%
Dec 31, 2019 18.59%
Sep 30, 2019 -26.28%
Jun 30, 2019 42.74%
Mar 31, 2019 42.36%
Dec 31, 2018 19.74%
Sep 30, 2018 46.87%
Jun 30, 2018 40.37%
Mar 31, 2018 42.32%
Dec 31, 2017 11.35%
Sep 30, 2017 58.54%
Jun 30, 2017 59.57%
Mar 31, 2017 57.91%
Dec 31, 2016 55.26%
Sep 30, 2016 58.65%
Jun 30, 2016 58.36%
Mar 31, 2016 59.67%
Dec 31, 2015 66.08%
Sep 30, 2015 67.33%
Jun 30, 2015 68.12%
Mar 31, 2015 70.73%
Dec 31, 2014 59.20%
Sep 30, 2014 57.60%
Jun 30, 2014 67.51%
Mar 31, 2014 60.87%
Dec 31, 2013 38.37%
Sep 30, 2013 41.25%
Jun 30, 2013 41.70%
Mar 31, 2013 40.49%
Dec 31, 2012 42.76%
Sep 30, 2012 43.02%
Jun 30, 2012 44.03%
Mar 31, 2012 35.06%
Dec 31, 2011 39.42%
Sep 30, 2011 47.31%
Jun 30, 2011 47.57%
Mar 31, 2011 46.83%
Dec 31, 2010 41.50%
Sep 30, 2010 50.53%
Jun 30, 2010 51.51%
Mar 31, 2010 55.67%
Dec 31, 2009 52.42%
Sep 30, 2009 49.65%
Jun 30, 2009 46.20%
Mar 31, 2009 52.82%